Swedish medical technology company VibroSense Dynamics AB (Spotlight Stock Market:VSD-B) announced on Wednesday that it has obtained provisional patent protection for its 'CIPN Prediction' patent application, addressing the assessment of potential permanent nerve damage resulting from cancer treatment with chemotherapy.

Published by the European Patent Office on 3 January 2024, this provisional protection provides safeguards against patent infringement.

The CIPN Prediction patent application outlines a method and biomarker for evaluating the risk of permanent nerve damage following various chemotherapy treatments. Leveraging this patent, the company's preliminary algorithm offers physicians a prognostic tool to aid in the selection of appropriate chemotherapy options.

Hans Wallin, CEO of VibroSense, said that collaborative research with external partners allows the company to maintain a dedicated focus on sales in the Diabetes and Occupational Health Care segments while advancing Oncology-related developments.